2-(5-fluoro-2-methoxyphenyl)thiophene

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-(5-fluoro-2-methoxyphenyl)thiophene
• 英文别名: 2-(Thien-2-yl)-4-fluoroanisole
• 化学式: C₁₁H₉FOS
• 分子量: 208.256
• InChiKey: OMUGBVKJRZTNHM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  37.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  二氯苯酚溴酯 、 2-(5-fluoro-2-methoxyphenyl)thiophene 在 四丁基碘化铵 、 三乙胺 作用下， 以 氯苯 为溶剂， 反应 24.0h， 以85%的产率得到8-fluoro-4-phenyl-4H-benzo[e]thieno[3,2-c][1,2]oxaborinine
  参考文献：
  名称：

  Iodide-Mediated or Iodide-Catalyzed Demethylation and Friedel–Crafts C–H Borylative Cyclization Leading to Thiophene-Fused 1,2-Oxaborine Derivatives

  摘要：

  The first synthesis of dithieno-1,2-oxaborine derivatives was achieved via iodide-mediated or iodide-catalyzed demethylation of 3-methoxy-2,2'-bithiophene and subsequent C-H borylation. A wide variety of thiophene-fused oxaborines could be synthesized by the procedure.

  DOI：

  10.1021/acs.orglett.9b00485
• 作为产物：
  描述：

  2-噻吩硼酸 、 2-溴-4-氟苯甲醚 在 二(三叔丁基膦)钯 、 sodium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 24.0h， 以98%的产率得到2-(5-fluoro-2-methoxyphenyl)thiophene
  参考文献：
  名称：

  Iodide-Mediated or Iodide-Catalyzed Demethylation and Friedel–Crafts C–H Borylative Cyclization Leading to Thiophene-Fused 1,2-Oxaborine Derivatives

  摘要：

  The first synthesis of dithieno-1,2-oxaborine derivatives was achieved via iodide-mediated or iodide-catalyzed demethylation of 3-methoxy-2,2'-bithiophene and subsequent C-H borylation. A wide variety of thiophene-fused oxaborines could be synthesized by the procedure.

  DOI：

  10.1021/acs.orglett.9b00485

文献信息

• Beta3 adrenergic agonists
  申请人：——

  公开号：US20030191156A1

  公开（公告）日：2003-10-09

  The present invention relates to a &bgr; 3 adrenergic receptor agonist of formula (I) or a pharmaceutical salt thereof, which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type II diabetes and/or obesity. The compound can also be used to lower triglyceride levels and cholesterol levels or raise high density lipoprotein levels or to decrease gut motility. In addition, the compound can be used to reduced neurogenic inflammation or as an antidepressant agent. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for decreasing gut motility are also disclosed.

  本发明涉及一种式(I)的&bgr;3肾上腺素受体激动剂或其药物盐，该激动剂能够增加细胞的脂解和能量消耗，因此可用于治疗II型糖尿病和/或肥胖症。该化合物还可用于降低甘油三酯水平和胆固醇水平或提高高密度脂蛋白水平或降低肠道蠕动。此外，该化合物还可用于减少神经源性炎症或作为抗抑郁剂。还公开了在治疗糖尿病和肥胖症以及降低甘油三酯水平和胆固醇水平或提高高密度脂蛋白水平或降低肠道蠕动方面使用该化合物的组合物和方法。
• &bgr;3 adrenergic agonists
  申请人：Eli Lilly and Company

  公开号：US06730792B2

  公开（公告）日：2004-05-04

  The present invention relates to a &bgr;3 adrenergic receptor agonist of formula (I) or a pharmaceutical salt thereof, which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type II diabetes and/or obesity. The compound can also be used to lower triglyceride levels and cholesterol levels or raise high density lipoprotein levels or to decrease gut motility. In addition, the compound can be used to reduced neurogenic inflammation or as an antidepressant agent. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for decreasing gut motility are also disclosed.

  本发明涉及一种化合物，其为式(I)的&bgr;3肾上腺素受体激动剂或其药物盐，能够增加细胞的脂解和能量消耗，因此可用于治疗II型糖尿病和/或肥胖症。该化合物还可用于降低甘油三酯水平和胆固醇水平，或提高高密度脂蛋白水平，或减少肠道运动。此外，该化合物还可用于减少神经源性炎症或作为抗抑郁剂。还公开了用于治疗糖尿病和肥胖症以及降低甘油三酯水平和胆固醇水平或提高高密度脂蛋白水平或减少肠道运动的化合物的组合物和使用方法。
• BETA3 ADRENERGIC AGONISTS
  申请人：ELI LILLY AND COMPANY

  公开号：EP1303509A1

  公开（公告）日：2003-04-23
• US6730792B2
  申请人：——

  公开号：US6730792B2

  公开（公告）日：2004-05-04
• [EN] BETA3 ADRENERGIC AGONISTS<br/>[FR] AGONISTES ADRENERGIQUES BETA3
  申请人：LILLY CO ELI

  公开号：WO2002006276A1

  公开（公告）日：2002-01-24

  The present invention relates to a β3 adrenergic receptor agonist of formula (I) or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type II diabetes and/or obesity. The compound can also be used to lower triglyceride levels and cholesterol levels or raise high density lipoprotein levels or to decrease gut motility. In addition, the compound can be used to reduced neurogenic inflammation or as an antidepressant agent. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for decreasing gut motility are also disclosed.